Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

医学 2型糖尿病 胰高血糖素样肽1受体 内科学 糖尿病 肾脏疾病 安慰剂 内分泌学 受体 兴奋剂 病理 替代医学
作者
Suetonia C. Palmer,Britta Tendal,Reem A. Mustafa,Per Olav Vandvik,Sheyu Li,Qiukui Hao,David J. Tunnicliffe,Marinella Ruospo,Patrizia Natale,Valeria Saglimbene,Antonio Nicolucci,David W. Johnson,Marcello Tonelli,Maria Chiara Rossi,Sunil V. Badve,Yeoungjee Cho,Annie‐Claire Nadeau‐Fredette,Michael Burke,Labib Imran Faruque,Anita Lloyd
标识
DOI:10.1136/bmj.m4573
摘要

Abstract Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk. Design Network meta-analysis. Data sources Medline, Embase, and Cochrane CENTRAL up to 11 August 2020. Eligibility criteria for selecting studies Randomised controlled trials comparing SGLT-2 inhibitors or GLP-1 receptor agonists with placebo, standard care, or other glucose lowering treatment in adults with type 2 diabetes with follow up of 24 weeks or longer. Studies were screened independently by two reviewers for eligibility, extracted data, and assessed risk of bias. Main outcome measures Frequentist random effects network meta-analysis was carried out and GRADE (grading of recommendations assessment, development, and evaluation) used to assess evidence certainty. Results included estimated absolute effects of treatment per 1000 patients treated for five years for patients at very low risk (no cardiovascular risk factors), low risk (three or more cardiovascular risk factors), moderate risk (cardiovascular disease), high risk (chronic kidney disease), and very high risk (cardiovascular disease and kidney disease). A guideline panel provided oversight of the systematic review. Results 764 trials including 421 346 patients proved eligible. All results refer to the addition of SGLT-2 inhibitors and GLP-1 receptor agonists to existing diabetes treatment. Both classes of drugs lowered all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and kidney failure (high certainty evidence). Notable differences were found between the two agents: SGLT-2 inhibitors reduced admission to hospital for heart failure more than GLP-1 receptor agonists, and GLP-1 receptor agonists reduced non-fatal stroke more than SGLT-2 inhibitors (which appeared to have no effect). SGLT-2 inhibitors caused genital infection (high certainty), whereas GLP-1 receptor agonists might cause severe gastrointestinal events (low certainty). Low certainty evidence suggested that SGLT-2 inhibitors and GLP-1 receptor agonists might lower body weight. Little or no evidence was found for the effect of SGLT-2 inhibitors or GLP-1 receptor agonists on limb amputation, blindness, eye disease, neuropathic pain, or health related quality of life. The absolute benefits of these drugs vary substantially across patients from low to very high risk of cardiovascular and renal outcomes (eg, SGLT-2 inhibitors resulted in 3 to 40 fewer deaths in 1000 patients over five years; see interactive decision support tool ( https://magicevidence.org/match-it/200820dist/#!/ ) for all outcomes. Conclusions In patients with type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists reduced cardiovascular and renal outcomes, with some differences in benefits and harms. Absolute benefits are determined by individual risk profiles of patients, with clear implications for clinical practice, as reflected in the BMJ Rapid Recommendations directly informed by this systematic review. Systematic review registration PROSPERO CRD42019153180.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lling完成签到 ,获得积分10
1秒前
听寒完成签到,获得积分10
3秒前
珍珠火龙果完成签到 ,获得积分10
6秒前
似水流年完成签到 ,获得积分10
7秒前
sysi完成签到 ,获得积分10
22秒前
绿波电龙完成签到,获得积分10
23秒前
26秒前
ZZzz完成签到 ,获得积分10
27秒前
wujiwuhui发布了新的文献求助10
31秒前
33秒前
梦梦的小可爱完成签到 ,获得积分10
33秒前
xinjie发布了新的文献求助10
36秒前
38秒前
蛋花肉圆汤完成签到,获得积分10
38秒前
羞涩的文轩完成签到 ,获得积分10
39秒前
44秒前
45秒前
北城完成签到 ,获得积分10
47秒前
量子星尘发布了新的文献求助10
47秒前
50秒前
爱听歌电灯胆完成签到 ,获得积分10
50秒前
不爱吃西葫芦完成签到 ,获得积分10
51秒前
申燕婷完成签到 ,获得积分10
52秒前
橙子完成签到 ,获得积分10
54秒前
ruochenzu发布了新的文献求助10
54秒前
fusheng完成签到 ,获得积分10
1分钟前
浮生完成签到 ,获得积分10
1分钟前
xinjie完成签到,获得积分10
1分钟前
Will完成签到,获得积分10
1分钟前
cuddly完成签到 ,获得积分10
1分钟前
掉头发的小白完成签到,获得积分10
1分钟前
不想看文献完成签到 ,获得积分10
1分钟前
1分钟前
当女遇到乔完成签到 ,获得积分10
1分钟前
独行者完成签到,获得积分10
1分钟前
眼睛大的电脑完成签到,获得积分10
1分钟前
1分钟前
敏敏发布了新的文献求助10
1分钟前
木木完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022